These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20854205)

  • 1. Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand.
    Briand N; Le Coeur S; Jourdain G; Hotrawarikarn S; Sirinontakan S; Hinjiranandana T; Kanjanavanit S; Traisathit P; McIntosh K; Lallemant M;
    AIDS Res Hum Retroviruses; 2010 Oct; 26(10):1163-6. PubMed ID: 20854205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.
    Briand N; Le Coeur S; Traisathit P; Karnchanamayul V; Hansudewechakul R; Ngampiyasakul C; Bhakeecheep S; Ithisukanan J; Hongsiriwon S; McIntosh K; Lallemant M
    Pediatr Infect Dis J; 2006 Apr; 25(4):325-32. PubMed ID: 16567984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
    Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
    Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand.
    Briand N; Pornprasert S; Ngo-Giang-Huong N; Galactéros F; Pissard S; Tatu T; Sanguansermsri T; Jourdain G; Lallemant M; Le Coeur S
    Antivir Ther; 2009; 14(1):117-22. PubMed ID: 19320245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.
    Feiterna-Sperling C; Weizsaecker K; Bührer C; Casteleyn S; Loui A; Schmitz T; Wahn V; Obladen M
    J Acquir Immune Defic Syndr; 2007 May; 45(1):43-51. PubMed ID: 17356471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.
    Culnane M; Fowler M; Lee SS; McSherry G; Brady M; O'Donnell K; Mofenson L; Gortmaker SL; Shapiro DE; Scott G; Jimenez E; Moore EC; Diaz C; Flynn PM; Cunningham B; Oleske J
    JAMA; 1999 Jan; 281(2):151-7. PubMed ID: 9917118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
    Connor EM; Sperling RS; Gelber R; Kiselev P; Scott G; O'Sullivan MJ; VanDyke R; Bey M; Shearer W; Jacobson RL
    N Engl J Med; 1994 Nov; 331(18):1173-80. PubMed ID: 7935654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    Lallemant M; Jourdain G; Le Coeur S; Mary JY; Ngo-Giang-Huong N; Koetsawang S; Kanshana S; McIntosh K; Thaineua V;
    N Engl J Med; 2004 Jul; 351(3):217-28. PubMed ID: 15247338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child-transmission of HIV in Tanzania.
    Ziske J; Kunz A; Sewangi J; Lau I; Dugange F; Hauser A; Kirschner W; Harms G; Theuring S
    PLoS One; 2013; 8(2):e55633. PubMed ID: 23405185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission.
    Taneepanichskul S; Sirinavin S; Phuapradit W; Chaturachinda K
    Aust N Z J Obstet Gynaecol; 1997 Aug; 37(3):329-31. PubMed ID: 9325519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
    Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
    JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.
    Lallemant M; Jourdain G; Le Coeur S; Kim S; Koetsawang S; Comeau AM; Phoolcharoen W; Essex M; McIntosh K; Vithayasai V
    N Engl J Med; 2000 Oct; 343(14):982-91. PubMed ID: 11018164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
    Bae WH; Wester C; Smeaton LM; Shapiro RL; Lockman S; Onyait K; Thior I; Essex M
    AIDS; 2008 Aug; 22(13):1633-40. PubMed ID: 18670224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine.
    Baroncelli S; Pinnetti C; Genovese O; Tamburrini E; Floridia M
    J Med Virol; 2011 Mar; 83(3):551-6. PubMed ID: 21264878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.
    Dryden-Peterson S; Shapiro RL; Hughes MD; Powis K; Ogwu A; Moffat C; Moyo S; Makhema J; Essex M; Lockman S
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):428-36. PubMed ID: 21266910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties.
    Fiscus SA; Adimora AA; Schoenbach VJ; Lim W; McKinney R; Rupar D; Kenny J; Woods C; Wilfert C
    JAMA; 1996 May; 275(19):1483-8. PubMed ID: 8622222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.
    Shaffer N; Chuachoowong R; Mock PA; Bhadrakom C; Siriwasin W; Young NL; Chotpitayasunondh T; Chearskul S; Roongpisuthipong A; Chinayon P; Karon J; Mastro TD; Simonds RJ
    Lancet; 1999 Mar; 353(9155):773-80. PubMed ID: 10459957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. New York City Perinatal HIV Transmission Collaborative Study Group.
    Abrams EJ; Matheson PB; Thomas PA; Thea DM; Krasinski K; Lambert G; Shaffer N; Bamji M; Hutson D; Grimm K
    Pediatrics; 1995 Sep; 96(3 Pt 1):451-8. PubMed ID: 7651777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.